Hemostatic Disorders: Clinical Trials

4,647 trials for Hemostatic Disorders, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

2206 completed, 636 recruiting, 582 terminated, 473 unknown. 1860 Phase 2, 1383 Phase 1, 470 Not applicable, 455 Phase 3, 97 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	1860	Completed 899, Terminated 292, Recruiting 196, Active not recruiting 160, Unknown 156, Withdrawn 97, Not yet recruiting 51, Suspended 6, Enrolling by invitation 3
Phase 1	1383	Completed 657, Terminated 242, Recruiting 170, Unknown 122, Active not recruiting 87, Withdrawn 53, Not yet recruiting 44, Suspended 8
Not applicable	470	Completed 203, Recruiting 91, Unknown 59, Terminated 52, Not yet recruiting 29, Active not recruiting 16, Withdrawn 14, Enrolling by invitation 3, Suspended 3
Phase 3	455	Completed 239, Recruiting 58, Active not recruiting 50, Unknown 48, Terminated 37, Not yet recruiting 13, Withdrawn 8, Suspended 2
Phase 4	97	Completed 44, Unknown 15, Recruiting 13, Terminated 8, Not yet recruiting 7, Active not recruiting 5, Withdrawn 5
Early Phase 1	96	Recruiting 30, Unknown 24, Not yet recruiting 14, Completed 11, Terminated 8, Active not recruiting 4, Withdrawn 3, Suspended 2

Follow Hemostatic Disorders: new trials by email Literature Review of Hemostatic Disorders trials Research Report on Hemostatic Disorders

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Effect of Ginger on Heavy Menstrual Bleeding in Women With Coagulation Disorders Ginger, Placebo - Women With Coagulation Disorders	Early Phase 1	Not yet recruiting	University of Valladolid	74	2028-02-01	2026-05-19
MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma Oncology-Embedded Cardiovascular Risk Assessment Pathway, Primary Care Provider-Directed Cardiovascular Risk Assessment Pathway - Multiple Myeloma, Heart Disease Risk Factors	Not applicable	Not yet recruiting	University of Vermont Medical Center	33	2028-02-01	2026-08-25
The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma Individual Exercise, Group Exercise - Multiple Myeloma	Not applicable	Suspended	Medical University of Vienna	45	2027-09-01	2026-10-09
Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulopathy • Sivelestat intravenous infusion, NaCl intravenous infusion - Septic Shock, Coagulopathy	Phase 2	Not yet recruiting	University Hospital, Strasbourg, France	120	2027-08-01	2026-08-20
Engineered Dendritic Cell Vaccines for Multiple Myeloma DC vaccines - Multiple Myeloma or Plasmacytoma	Phase 1	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	10	2027-06-30	2026-08-27
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma	Phase 1	Withdrawn	Fred Hutchinson Cancer Center		2027-06-01	2026-09-11
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma	Phase 2	Recruiting	National Cancer Institute (NCI)	80	2027-05-22	2026-10-28
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma	Phase 1 / Phase 2	Recruiting	National Cancer Institute (NCI)	162	2027-04-12	2026-10-16
Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy ceftazidime, ciprofloxacin, Standard-of-Care Antibiotic Strategy - Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM)	Phase 2	Not yet recruiting	Zealand University Hospital	150	2027-03-01	2026-09-25
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy - Multiple Myeloma (MM)	Phase 2	Not yet recruiting	University of Arkansas	50	2027-03-01	2026-09-02
An Exercise and Lifestyle Programme for Adults With Vascular Ehlers-Danlos Syndrome: A Feasibility Study Co-designed exercise-based lifestyle intervention - Vascular Ehlers Danlos Syndrome	Not applicable	Not yet recruiting	Sheffield Hallam University	40	2027-03-01	2026-07-13
BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. teclistamab OR talquetamab OR elranatamab OR linvoseltamab, BTK inhibitors (ibrutinib and zanubrutinib) - Waldenstrom Macroglobulinaemia, Multiple Myeloma	Phase 4	Not yet recruiting	Anne Louise Tølbøll Sørensen	400	2027-03-01	2026-03-16
Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART) Live Biotherapeutic Product (LBP), Placebo - Lymphoma, B-Cell, Multiple Myeloma	Phase 1	Not yet recruiting	University of Chicago	32	2027-02-23	2026-10-22
Teclistamab In Waldenstrom's Macroglobulinemia Teclistamab - Waldenstrom's Macroglobulinemia	Phase 2	Not yet recruiting	Massachusetts General Hospital	24	2027-02-19	2026-09-01
Regenerative Medicine for Joint Hypermobility and Instability Dextrose 20% Prolotherapy, Autologous Platelet-Rich Plasma, Doxycycline Hyclate Injectable (Investigational) - Ehlers-Danlos Syndrome Hypermobility Type (hEDS), Ehlers-Danlos Syndrome (EDS)	Phase 1 / Phase 2	Not yet recruiting	Manhattan Pain Medicine, PLLC	100	2027-01-15	2026-10-06
Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization rhTPO prophylaxis plus EAP stem-cell mobilization - Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization	Phase 2 / Phase 3	Not yet recruiting	The Affiliated People's Hospital of Ningbo University	70	2027-01-01	2026-09-30
Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells Isatuximab, VRD - Multiple Myeloma	Phase 2 / Phase 3	Not yet recruiting	The Affiliated People's Hospital of Ningbo University	15	2027-01-01	2026-10-02
A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma Anitocabtagene autoleucel, Daratumumab, Bortezomib - Newly Diagnosed Multiple Myeloma	Phase 3	Not yet recruiting	Kite, A Gilead Company	600	2027-01-01	2026-10-21
Phase 1b Study of TX002100 in Participants With Hematologic Support-Dependent Hereditary Hemorrhagic Telangiectasia (HHT) TX002100 - Hereditary Hemorrhagic Telangiectasia (HHT)	Phase 1	Not yet recruiting	Tectonic Operating Company, Inc.	20	2026-12-31	2026-10-15
Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma CAR T cells - Multiple Myeloma	Phase 1 / Phase 2	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	20	2026-12-31	2026-08-27

Hemostatic Disorders: Clinical Trials

4,647 trials for Hemostatic Disorders, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

By phase and status

Trials newest first · largest first

Narrower conditions

Broader conditions

Interventions

Sponsors

Countries

Top investigators

Results publications

NIH funding